Developing a mitochondrial gene risk for patients with neurodegenerative and neuropsychiatric diseases.

Neurodegenerative diseases represent one of the largest healthcare burdens in Canada. However, there is limited understanding of how the complex biological factors affect the development of neurodegenerative diseases, thus the era of precision medicine has not to come to treat them yet. Here, we take focus on bioenergetic disruption as a shared risk factor of neurodegenerative diseases and common conditions as type 2 diabetes, psychiatric disorders, and cardiovascular diseases. Hence, we apply machine learning techniques to analyze sets of biological measurements related to mitochondria – the powerhouse of the cell controlling bioenergetics – to identify biological factors that contribute to risk of developing neurodegenerative diseases and related conditions. NetraMark’s novel AI will analyze how diseases can be stratified based on biological markers, and the results will be added to their analytic depository for further algorithmic development. MitoCanada Foundation will deliver novel findings to patients, clinicians, and scientists in approachable medium to accelerate mitochondrial research and education.

Faculty Supervisor:

Ana Andreazza

Student:

Partner:

NetraMark Corp;MitoCanada Foundation

Discipline:

Life Sciences

Sector:

Professional, scientific and technical services

University:

University of Toronto

Program: